Cellectar Biosciences Announces Results of In Vivo Study Demonstrating PDC Platform Delivery of Paclitaxel to be Superior in ...
15 Juni 2016 - 2:30PM
Cellectar Biosciences, Inc. (Nasdaq:CLRB) ("the company"), an
oncology-focused biotechnology company, today announces the results
of a preliminary tumor-targeting study that shows its prototype
paclitaxel chemotherapeutic conjugate, CLR 1602, may be up to 30
times more tumor selective in comparison to free paclitaxel.
The preliminary in vivo study demonstrated that tumor uptake of
CLR 1602’s paclitaxel payload increased by more than 30-fold over
free paclitaxel, and also displayed an extended plasma half-life
relative to free paclitaxel. The extended plasma half-life may, in
part, explain the enhanced tumor uptake. Unlike free paclitaxel,
which was rapidly cleared from plasma within 24 hours, CLR 1602
displayed prolonged retention even at 96 hours.
“The study results are a significant signal in the development
of our paclitaxel Phospholipid Drug Conjugates (PDCs). More
importantly, it represents further validation of our entire CLR CTX
program,” said Jim Caruso, president and CEO of Cellectar
Biosciences. “These data clearly confirm our ongoing assertion that
delivery of chemotherapeutics with our PDC platform may provide
superior tumor cell targeting than chemotherapeutics alone,
converting non-targeted chemotherapeutics into targeted cytotoxic
agents. We anticipate conducting future studies and
evaluating against other comparators, such as Abraxane™.”
The study was designed to assess the pharmacokinetics,
absorption, and distribution after a single intravenous
administration of CLR 1602, (N=24) a paclitaxel PDC vs. free
paclitaxel (N=24) in tumor bearing mice. In this biodistribution
study, CLR 1602, a paclitaxel Cremophor EL-free formulation
(formulated without Cremophor, which is believed to contribute to
free paclitaxel adverse event profile), was compared to free
paclitaxel at equivalent sub-therapeutic concentrations in an
effort to demonstrate enhanced CLR 1602 tumor targeting vs. free
paclitaxel.
“This promising new in vivo paclitaxel data further confirms the
tumor targeting selectivity of our PDC carrier, which has been
consistently observed with oncology therapeutics and imaging
agents. With targeting confirmed we will now optimize the PDC
linker with the aim of enhancing the cytotoxic impact on cancer
cells,” said Jamey Weichert, Ph.D., founder and chief scientific
officer of Cellectar Biosciences. “Furthermore, these results
validate our ‘tool kit’ concept whereby carbon-14 labeled versions
of our PDCs are utilized to quickly assess the potential tumor
targeting enhancement that our PDC delivery system may afford to
existing or new chemotherapeutic agents.”
These quantitative results comparing biodistribution of CLR 1602
vs. free paclitaxel will be the subject of a poster presented at
the 35th National Medicinal Chemistry Symposium in Chicago, June
26-29. The company also anticipates further data to be
presented at another conference later this year.
About Cellectar Biosciences, Inc. Cellectar
Biosciences is developing phospholipid drug conjugates (PDCs)
designed to provide cancer targeted delivery of diverse oncologic
payloads to a broad range of cancers and cancer stem cells.
Cellectar's PDC Delivery Platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules
have demonstrated highly selective uptake and retention in a broad
range of cancers. Cellectar's PDC pipeline includes product
candidates for cancer therapy and cancer diagnostic imaging. The
company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a
cytotoxic radioisotope, as its payload. CLR 131 is currently being
evaluated under an orphan drug designated Phase 1 study in patients
with relapsed or refractory multiple myeloma. The company is
actively developing PDCs for targeted delivery of chemotherapeutics
such as paclitaxel (CLR 1602-PTX), a preclinical stage product
candidate, and plans to expand its PDC chemotherapeutic pipeline
through both in-house and collaborative R&D efforts. For
additional information please visit
www.cellectarbiosciences.com
This news release contains forward-looking statements. You can
identify these statements by our use of words such as "may,"
"expect," "believe," "anticipate," "intend," "could," "estimate,"
"continue," "plans," or their negatives or cognates. These
statements are only estimates and predictions and are subject to
known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and
commercialize drug candidates, competition from other
pharmaceutical companies, product pricing and third-party
reimbursement. A complete description of risks and uncertainties
related to our business is contained in our periodic reports filed
with the Securities and Exchange Commission including our Form 10-K
for the year ended December 31, 2015. These forward-looking
statements are made only as of the date hereof, and we disclaim any
obligation to update any such forward-looking statements.
INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Cellectar Biosciences (NASDAQ:CLRBW)
Historical Stock Chart
Von Jul 2023 bis Jul 2024